All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2016-12-20T15:49:21.000Z

Waldenström macroglobulinemia: Six-year follow-up of phase II trial into front-line BDR in the treatment of newly diagnosed patients

Dec 20, 2016
Share:

Bookmark this article

In November 2016, Maria Gavriatopoulou from the National and Kapodistrian University of Athens School of Medicine, Greece, and colleagues published in Blood the results of the six-year follow-up of a multi-center phase II study into the efficacy of chemotherapy-free bortezomib, dexamethasone, and rituximab (BDR) in newly diagnosed WM patients. The study enrolled 59 patients over 10 centers in Europe.

The BDR treatment regimen was 23 weeks long; the first cycle was 21 days with bortezomib IV 1.3mg/m2 on days 1, 4, 8, and 11. Bortezomib was then administered weekly for a further four 35-day cycles at 1.6mg/m2. On cycles 2 and 5, IV dexamethasone and IV rituximab were also delivered at 40mg and 375mg/m2 doses, respectively. 

Highlights:

  • Majority of patients recruited were intermediate (40%) or high (45.5%) according to IPSSWM
  • ITT analysis:
    • 85% responded with 3% CR, 7% VGPR, 58% PR, 17% MR
    • Major response rate (PR + VGPR + CR) of 68%
  • Median PFS: 43 months (with 17% in remission after a median of 90 months)
  • 7-year PFS and 7-year OS by risk:
    • Low IPSSWM = 62.5% and 87.5%
    • Intermediate IPSSWM = 42% and 68.2%
    • High IPSSWM = 15% and 48%
  • 7-year overall OS = 66%
  • Peripheral neuropathy in 46% patients, but this resolved completely or to grade I

The authors concluded by stating that toxicity was mild and that BDR was an active chemotherapy-free treatment, which was shown to result in durable responses over a 6 year follow-up period.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 49 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox